Breaking the Cycle: How Modafinil Offers Hope for Sleep and Mood Disorders in HIV Patients

Introduction: The Hidden Epidemic of Sleep and Mood Disorders in HIV

Nearly 40 million people worldwide live with HIV, a condition that has transformed from a fatal infection into a manageable chronic disease thanks to advances in antiretroviral therapy (ART). However, beyond viral suppression and immune restoration, many individuals face deep, persistent challenges—especially sleep disorders and emotional distress—that severely impact quality of life. Recent studies report that up to 70% of HIV-infected individuals experience obstructive sleep apnea (OSA), significantly higher than the estimated global prevalence of 1 billion people affected by sleep apnea overall. Sleep disruptions not only degrade daily functioning but also create a vicious cycle with psychiatric symptoms such as depression and anxiety, which themselves worsen sleep. This article explores the complex interplay between HIV infection, sleep disturbances, and mood disorders, diving into emerging evidence on how the wakefulness-promoting agent modafinil can become a game changer in this clinical arena.

Sleep Disorders in People Living with HIV: Scope and Mechanisms